George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted to insider trading for selling more than 60,000 Acadia ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research ...

Sei Investments Co. lifted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 57.4% during the 4th quarter, according to its most recent 13F filing with the SEC.

SAN DIEGO, April 11, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq ... Acadia’s closing trading price on April 3, 2025, and will vest over four years, with 25% of the underlying ...

Acadia Pharmaceuticals Inc. (Nasdaq ... an exercise price per share equal to $16.12 per share, Acadia’s closing trading price on April 3, 2025, and will vest over four years, with 25% of ...